Literature DB >> 30349610

A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism.

Philippe Colucci1, Corinne Seng Yue2, Murray Ducharme3, Salvatore Benvenga4.   

Abstract

Thyroxine hormone has been recognised since the early part of the nineteenth century and levothyroxine has been available since the mid-nineteenth century as a replacement for deficient thyroid hormones. While levothyroxine remains the staple treatment for hypothyroidism even to this day, its optimal use can be challenging. As is often the case with older drugs, the pharmacokinetics of levothyroxine is often under-appreciated or misunderstood and many factors influence the optimal dosing of levothyroxine. This article will review the pharmacokinetics of levothyroxine in the treatment of hypothyroidism and highlight major concepts that should aid both clinicians and researchers.

Entities:  

Keywords:  Pharmacokinetics; drugs formulations; hypothyroidism; interactions between drugs; intestinal absorption; levothyroxine

Year:  2013        PMID: 30349610      PMCID: PMC6193522          DOI: 10.17925/EE.2013.09.01.40

Source DB:  PubMed          Journal:  Eur Endocrinol        ISSN: 1758-3772


  173 in total

1.  Abnormal TSH: a rational approach to the older patient.

Authors:  P J Drinka
Journal:  Geriatrics       Date:  1999-08

2.  A bioequivalence study of levothyroxine tablets versus an oral levothyroxine solution in healthy volunteers.

Authors:  N Yannovits; E Zintzaras; A Pouli; G Koukoulis; S Lyberi; E Savari; S Potamianos; F Triposkiadis; I Stefanidis; E Zartaloudis; A Benakis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2006 Apr-Jun       Impact factor: 2.441

3.  The influence of cholestyramine on thyroxine absorption.

Authors:  R C Northcutt; J N Stiel; J W Hollifield; E G Stant
Journal:  JAMA       Date:  1969-06-09       Impact factor: 56.272

4.  Serum thyroid hormone levels in patients with liver disease.

Authors:  G W Hepner; I J Chopra
Journal:  Arch Intern Med       Date:  1979-10

5.  Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.

Authors:  K A Steingold; D W Matt; D DeZiegler; J E Sealey; M Fratkin; S Reznikov
Journal:  J Clin Endocrinol Metab       Date:  1991-08       Impact factor: 5.958

Review 6.  Levothyroxine therapy in patients with thyroid disease.

Authors:  S J Mandel; G A Brent; P R Larsen
Journal:  Ann Intern Med       Date:  1993-09-15       Impact factor: 25.391

7.  Long term therapy with a new liquid L-thyroxine preparation: bioequivalence with L-T4 tablets.

Authors:  A Carpi; M G Toni; M Maccheroni; C De Gaudio
Journal:  Thyroidology       Date:  1992-12

8.  Increased thyroxine turnover and thyroidal function after stimulation of hepatocellular binding of thyroxine by phenobarbital.

Authors:  J H Oppenheimer; G Bernstein; M I Surks
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808

9.  Soy formula complicates management of congenital hypothyroidism.

Authors:  S C Conrad; H Chiu; B L Silverman
Journal:  Arch Dis Child       Date:  2004-01       Impact factor: 3.791

10.  Long-term efficacy and tolerability of octreotide treatment in acromegaly.

Authors:  S E Christensen; J Weeke; H Orskov; A Kaal; E Lund; J Jørgensen; A G Harris
Journal:  Metabolism       Date:  1992-09       Impact factor: 8.694

View more
  30 in total

1.  Patients with lactose intolerance absorb liquid levothyroxine better than tablet levothyroxine.

Authors:  Poupak Fallahi; Silvia Martina Ferrari; Santino Marchi; Nicola De Bortoli; Ilaria Ruffilli; Alessandro Antonelli
Journal:  Endocrine       Date:  2016-08-30       Impact factor: 3.633

Review 2.  Thyroid hormone therapy in congenital hypothyroidism and pediatric hypothyroidism.

Authors:  Andrew J Bauer; Ari J Wassner
Journal:  Endocrine       Date:  2019-07-26       Impact factor: 3.633

3.  In thyroxine-replaced hypothyroid postmenopausal women under simultaneous calcium supplementation, switch to oral liquid or softgel capsule L-thyroxine ensures lower serum TSH levels and favorable effects on blood pressure, total cholesterolemia and glycemia.

Authors:  Elisabetta Morini; Antonino Catalano; Antonino Lasco; Nunziata Morabito; Salvatore Benvenga
Journal:  Endocrine       Date:  2019-03-27       Impact factor: 3.633

4.  Economic Evaluation of a Pharmacist-Led 5-Day Therapeutic Hold of IV Levothyroxine at an Academic Medical Center.

Authors:  Blake T Barlow; Russel J Roberts; Kelly Newman; Sarah K Harrison; Jonathan H Sin
Journal:  Hosp Pharm       Date:  2020-11-09

5.  Should patients skip late doses of medication? A pharmacokinetic perspective.

Authors:  Elias D Clark; Sean D Lawley
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-06-20       Impact factor: 2.410

Review 6.  Pharmacokinetics and Clinical Implications of Two Non-Tablet Oral Formulations of L-Thyroxine in Patients with Hypothyroidism.

Authors:  Pierpaolo Trimboli; Stéphane Mouly
Journal:  J Clin Med       Date:  2022-06-16       Impact factor: 4.964

Review 7.  Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans.

Authors:  Il-Sup Kim
Journal:  Antioxidants (Basel)       Date:  2021-06-30

8.  L-thyroxine malabsorption due to calcium carbonate impairs blood pressure, total cholesterolemia, and fasting glycemia.

Authors:  Elisabetta Morini; Antonino Catalano; Antonino Lasco; Nunziata Morabito; Salvatore Benvenga
Journal:  Endocrine       Date:  2018-10-27       Impact factor: 3.633

9.  Changes of Drug Pharmacokinetics in Patients with Short Bowel Syndrome: A Systematic Review.

Authors:  Wallace Bok-Thoe Hong; Wee Kiat Tan; Lawrence Siu-Chun Law; David Eng-Hui Ong; Elaine Ah-Gi Lo
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-07-01       Impact factor: 2.441

10.  l-Thyroxine in an Oral Liquid or Softgel Formulation Ensures More Normal Serum Levels of Free T4 in Patients with Central Hypothyroidism.

Authors:  Salvatore Benvenga; Giovanni Capodicasa; Sarah Perelli
Journal:  Front Endocrinol (Lausanne)       Date:  2017-11-20       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.